Drugs as CYP3A Probes, Inducers, and Inhibitors

Human cytochrome P450 (CYP) 3A subfamily members (mainly CYP3A4 and CYP3A5) mediate the metabolism of approximately half all marketed drugs and thus play a critical role in the drug metabolism. A huge number of studies on CYP3A-mediated drug metabolism in humans have demonstrated that CYP3A activity exhibits marked ethnic and individual variability, in part because of altered levels of CYP3A4 expression by various environmental factors and functionally important polymorphisms present in CYP3A5 gene. Accumulating evidence has revealed that CYP3A4 and CYP3A5 have a significant overlapping in their substrate specificity, inducers and inhibitors. Therefore, it is difficult to define their respective contribution to drug metabolism and drug-drug interactions. Furthermore, P-glycoprotein and CYP3A are frequently co-expressed in the same cells and share a large number of substrates and modulators. The disposition of such drugs is thus affected by both metabolism and transport. In this review, we systematically summarized the frequently used CYP3A probe drugs, inducers and inhibitors, and evaluated their current status in drug development and research.

[1]  A. Mitra,et al.  Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs. , 2001, Pharmacogenomics.

[2]  Uichi Ikeda,et al.  Expression and induction of CYP3As in human fetal hepatocytes. , 2004, Biochemical and biophysical research communications.

[3]  G. M. Pollack,et al.  Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[4]  Shiew-Mei Huang,et al.  Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[5]  B. Guglielmo,et al.  In vivo Effect of I'm-Yunity™ on Hepatic Cytochrome P450 3A4 , 2007, Journal of herbal pharmacotherapy.

[6]  J S Harmatz,et al.  Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. , 1996, The Journal of pharmacology and experimental therapeutics.

[7]  A. Y. Lu,et al.  Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[8]  J. D. de Vries,et al.  Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate‐binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms , 2007, Fundamental & clinical pharmacology.

[9]  D. Greger,et al.  Effects of dexamethasone on mRNA abundance of nuclear receptors and hepatic nuclear receptor target genes in neonatal calves. , 2007, Journal of animal physiology and animal nutrition.

[10]  C. Emoto,et al.  In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations in human liver microsomes: a comparison with SKF-525A. , 2005, Drug metabolism and pharmacokinetics.

[11]  M. Hebert,et al.  EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO , 2006, Drug Metabolism and Disposition.

[12]  J. Verweij,et al.  Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients , 2004, Clinical Cancer Research.

[13]  L. Benet,et al.  Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy , 1995, Molecular carcinogenesis.

[14]  J. Marois,et al.  Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fluorescent probe. , 1999, Analytical biochemistry.

[15]  A. Li,et al.  Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. , 2001, Chemico-biological interactions.

[16]  H. Yamazaki,et al.  CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. , 2004, Drug metabolism and pharmacokinetics.

[17]  David J Greenblatt,et al.  Interaction of triazolam and ketoconazole in P-glycoprotein-deficient mice. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[18]  K. Brøsen,et al.  A Comparative Pharmacokinetic Study in Healthy Volunteers of the Effect of Carbamazepine and Oxcarbazepine on Cyp3a4 , 2007, Epilepsia.

[19]  A. Gaedigk,et al.  Coadministration of Lopinavir/Ritonavir and Phenytoin Results in Two-Way Drug Interaction Through Cytochrome P-450 Induction , 2004, Journal of acquired immune deficiency syndromes.

[20]  C. Wolf,et al.  Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance. , 2000, The Journal of pharmacology and experimental therapeutics.

[21]  B. Ring,et al.  Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[22]  Karthik Venkatakrishnan,et al.  Human Drug Metabolism and the Cytochromes P450: Application and Relevance of In Vitro Models , 2001, Journal of clinical pharmacology.

[23]  S. D. Turner,et al.  Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[24]  M. Galteau,et al.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. , 2003, European journal of clinical pharmacology.

[25]  J. Goldstein,et al.  The constitutive active/androstane receptor regulates phenytoin induction of Cyp2c29. , 2004, Molecular pharmacology.

[26]  A. D. Rodrigues,et al.  Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism. , 1999, The Journal of pharmacology and experimental therapeutics.

[27]  L. Wienkers,et al.  Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[28]  S. Hall,et al.  DIFFERENTIAL MECHANISM-BASED INHIBITION OF CYP3A4 AND CYP3A5 BY VERAPAMIL , 2005, Drug Metabolism and Disposition.

[29]  Mark M. Roden,et al.  Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein , 1999, Pharmaceutical Research.

[30]  D. Greenblatt,et al.  In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[31]  M. Huang,et al.  Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs , 2005, Clinical pharmacokinetics.

[32]  J. Brockmöller,et al.  Limited contribution of CYP3A5 to the hepatic 6β-hydroxylation of testosterone , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[33]  J B Houston,et al.  CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. , 1999, British journal of clinical pharmacology.

[34]  A. Kong,et al.  Induction of phase I, II and III drug metabolism/transport by xenobiotics , 2005, Archives of pharmacal research.

[35]  P. Watkins.  Noninvasive tests of CYP3A enzymes. , 1994, Pharmacogenetics.

[36]  P. Watkins,et al.  CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition. , 2005, Molecular interventions.

[37]  Kazuhiko Tanaka,et al.  Urinary 6β-hydroxycortisol/17-hydroxycorticosteroids ratio as a measure of hepatic CYP3A4 capacity after enzyme induction , 2004, Annals of clinical biochemistry.

[38]  J. Kolars,et al.  Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[39]  Kiyomi Ito,et al.  CYP3A4 Substrate Selection and Substitution in the Prediction of Potential Drug-Drug Interactions , 2005, Journal of Pharmacology and Experimental Therapeutics.

[40]  Hong-Guang Xie,et al.  St John's wort‐associated drug interactions: Short‐term inhibition and long‐term induction? , 2005, Clinical pharmacology and therapeutics.

[41]  B. Jones,et al.  In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole. , 2003, Drug metabolism and pharmacokinetics.

[42]  J. Pascussi,et al.  Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. , 2001, European journal of biochemistry.

[43]  D. Shen,et al.  Can oral midazolam predict oral cyclosporine disposition? , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[44]  L. Benet,et al.  Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. , 2002, The Journal of pharmacology and experimental therapeutics.

[45]  B. W. Penman,et al.  Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. , 1997, Analytical biochemistry.

[46]  L. Benet,et al.  Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. , 2003, Current drug metabolism.

[47]  A. Takagi,et al.  Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. , 2005, Biological & pharmaceutical bulletin.

[48]  E. Schuetz,et al.  Genetic contribution to variable human CYP3A-mediated metabolism. , 2002, Advanced drug delivery reviews.

[49]  H. Yamazaki,et al.  Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5' modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. , 1995, Archives of biochemistry and biophysics.

[50]  A. Bell,et al.  Phenobarbital regulates nuclear expression of HNF‐4α in mouse and rat hepatocytes independent of CAR and PXR , 2006, Hepatology.

[51]  Hongbing Wang,et al.  Role of Orphan Nuclear Receptors in the Regulation of Drug-Metabolising Enzymes , 2003, Clinical pharmacokinetics.

[52]  A. Mitra,et al.  MDR- and CYP3A4-mediated drug-herbal interactions. , 2006, Life sciences.

[53]  W. L. Nelson,et al.  ROLE OF ITRACONAZOLE METABOLITES IN CYP3A4 INHIBITION , 2004, Drug Metabolism and Disposition.

[54]  Aleksandra Galetin,et al.  UTILITY OF RECOMBINANT ENZYME KINETICS IN PREDICTION OF HUMAN CLEARANCE: IMPACT OF VARIABILITY, CYP3A5, AND CYP2C19 ON CYP3A4 PROBE SUBSTRATES , 2004, Drug Metabolism and Disposition.

[55]  M. Galteau,et al.  Urinary 6β-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals , 2003, European Journal of Clinical Pharmacology.

[56]  U. Yasar,et al.  Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[57]  Slobodan Petar Rendic.  Summary of information on human CYP enzymes: human P450 metabolism data , 2002, Drug metabolism reviews.

[58]  F. Guengerich.  Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. , 1990, Chemical research in toxicology.

[59]  R. Gaedigk,et al.  NUCLEAR RECEPTOR EXPRESSION IN FETAL AND PEDIATRIC LIVER: CORRELATION WITH CYP3A EXPRESSION , 2006, Drug Metabolism and Disposition.

[60]  L. Bertilsson,et al.  Metabolism and elimination of quinine in healthy volunteers , 2003, European Journal of Clinical Pharmacology.

[61]  R. Kim,et al.  Genetic variability in CYP3A5 and its possible consequences. , 2004, Pharmacogenomics.

[62]  Kyoung-Ah Kim,et al.  Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects , 2006, Clinical pharmacology and therapeutics.

[63]  R. Kim,et al.  P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. , 1999, Cancer research.

[64]  Mary F Paine,et al.  THE HUMAN INTESTINAL CYTOCHROME P450 “PIE” , 2006, Drug Metabolism and Disposition.

[65]  R. Riley,et al.  Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5 , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[66]  Kiyomi Ito,et al.  Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[67]  Weili Huang,et al.  EVIDENCE OF SIGNIFICANT CONTRIBUTION FROM CYP3A5 TO HEPATIC DRUG METABOLISM , 2004, Drug Metabolism and Disposition.

[68]  M. Tarbit,et al.  A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[69]  Y Zhang,et al.  The Gut as a Barrier to Drug Absorption , 2001, Clinical pharmacokinetics.

[70]  T. Ishizaki,et al.  An in vitro study on the metabolism and possible drug interactions of rokitamycin, a macrolide antibiotic, using human liver microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[71]  E. Schuetz,et al.  Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. , 1996, Molecular pharmacology.

[72]  E. Kharasch,et al.  Single‐point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam , 2005, Clinical pharmacology and therapeutics.

[73]  J. Brockmöller,et al.  The Induction of Cytochrome P450 3A5 (CYP3A5) in the Human Liver and Intestine Is Mediated by the Xenobiotic Sensors Pregnane X Receptor (PXR) and Constitutively Activated Receptor (CAR)* , 2004, Journal of Biological Chemistry.

[74]  A. Y. Lu,et al.  Interindividual variability in inhibition and induction of cytochrome P450 enzymes. , 2001, Annual review of pharmacology and toxicology.

[75]  M. D'antoni,et al.  Use of a benzyloxy-substituted lactone cyclooxygenase-2 inhibitor as a selective fluorescent probe for CYP3A activity in primary cultured rat and human hepatocytes. , 2004 .

[76]  R. Kim,et al.  Nuclear receptors and drug disposition gene regulation. , 2005, Journal of pharmaceutical sciences.

[77]  U. Yasar,et al.  A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes. , 2003, Pharmacology & toxicology.

[78]  P. Beaune,et al.  In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes. , 1999, The Journal of pharmacology and experimental therapeutics.

[79]  L. Wojnowski,et al.  Cytochrome P450 3A and their regulation , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[80]  S. Wrighton,et al.  Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). , 1990, Molecular pharmacology.

[81]  Jennifer L. Donovan,et al.  Comparative CYP3A4 Inhibitory Effects of Venlafaxine, Fluoxetine, Sertraline, and Nefazodone in Healthy Volunteers , 2004, Journal of clinical psychopharmacology.

[82]  J. Gorski,et al.  The effect of short‐ and long‐term administration of verapamil on the disposition of cytochrome P450 3A and P‐glycoprotein substrates , 2006, Clinical pharmacology and therapeutics.

[83]  A. Nafziger,et al.  Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. , 2000, Pharmacogenetics.

[84]  P. Neuvonen,et al.  Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations , 1998, Clinical pharmacology and therapy.

[85]  R. Kim.  Drugs as P-glycoprotein substrates, inhibitors, and inducers , 2002, Drug metabolism reviews.

[86]  J. Raucy.  Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[87]  Sean Kim,et al.  CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[88]  D. Greenblatt,et al.  Methodologies to study the induction of rat hepatic and intestinal cytochrome P450 3A at the mRNA, protein, and catalytic activity level. , 2000, Journal of pharmacological and toxicological methods.

[89]  R. Kim,et al.  Molecular basis of ethnic differences in drug disposition and response. , 2001, Annual review of pharmacology and toxicology.

[90]  Y. Horsmans,et al.  CYP3A4 activity in four different animal species liver microsomes using 7-benzyloxyquinoline and HPLC/spectrofluorometric determination. , 2006, Journal of pharmaceutical and biomedical analysis.

[91]  P. Beaune,et al.  Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.

[92]  Y Vanrenterghem,et al.  Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [14C]erythromycin breath and urine test. , 2003, American journal of physiology. Gastrointestinal and liver physiology.

[93]  David J. Greenblatt,et al.  Clinical Pharmacokinetics of Alprazolam , 1993, Clinical pharmacokinetics.

[94]  J. Falk,et al.  Differential reinforcement of low rate performance, pharmacokinetics and pharmacokinetic-pharmacodynamic modeling: independent interaction of alprazolam and caffeine. , 1997, The Journal of pharmacology and experimental therapeutics.

[95]  E. Schuetz,et al.  Expression of cytochrome P450 3A in amphibian, rat, and human kidney. , 1992, Archives of biochemistry and biophysics.

[96]  Y. Sugiyama,et al.  In Vitro/in Vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans , 2001, Biopharmaceutics & drug disposition.

[97]  P. Watkins,et al.  Bimodal distribution of renal cytochrome P450 3A activity in humans. , 1996, Molecular pharmacology.

[98]  D. Waxman,et al.  Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. , 1994, Archives of biochemistry and biophysics.

[99]  S. Wrighton,et al.  Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers , 1993, Antimicrobial Agents and Chemotherapy.

[100]  L. Bertilsson,et al.  Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man , 2003, European Journal of Clinical Pharmacology.

[101]  E. Kharasch,et al.  Pharmacogenetic Determinants of Human Liver Microsomal Alfentanil Metabolism and the Role of Cytochrome P450 3A5 , 2005, Anesthesiology.

[102]  臼井 達洋,et al.  Induction of CYP3As in HepG2 Cells by Several Drugs. - Association between Induction of CYP3A4 and Expression of Glucocorticoid Receptor -. , 2005 .

[103]  E. Ezan,et al.  Erythromycin increases plasma concentrations of α‐dihydroergocryptine in humans , 2001, Clinical pharmacology and therapeutics.

[104]  S. D. Turner,et al.  Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[105]  Michael Oellerich,et al.  Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. , 2005, Clinical chemistry.

[106]  O Pelkonen,et al.  Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line. , 2000, American journal of respiratory cell and molecular biology.

[107]  N. Chalasani,et al.  Inhibition of Human Intestinal Wall Metabolism by Macrolide Antibiotics: Effect of Clarithromycin on Cytochrome P450 3A4/5 Activity and Expression , 2005, Clinical pharmacology and therapeutics.

[108]  Y. Kasuya,et al.  Evidence for the validity of cortisol 6 beta-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[109]  D. Greenblatt,et al.  Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate , 2004, Clinical pharmacology and therapeutics.

[110]  K. Yeo,et al.  Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. , 2001, British journal of clinical pharmacology.

[111]  Jennifer B Dennison,et al.  SELECTIVE METABOLISM OF VINCRISTINE IN VITRO BY CYP3A5 , 2006, Drug Metabolism and Disposition.

[112]  M. Tonato,et al.  Pharmacokinetics of vincristine in cancer patients treated with nifedipine , 1989, Cancer.

[113]  D. Greenblatt,et al.  FACTORS INFLUENCING MIDAZOLAM HYDROXYLATION ACTIVITY IN HUMAN LIVER MICROSOMES , 2006, Drug Metabolism and Disposition.

[114]  E. Kharasch,et al.  Intravenous and oral alfentanil as in vivo probes for hepatic and first‐pass cytochrome P450 3A activity: Noninvasive assessment by use of pupillary miosis , 2004, Clinical pharmacology and therapeutics.

[115]  F. Guengerich,et al.  Cooperativity in oxidations catalyzed by cytochrome P450 3A4. , 1997, Biochemistry.

[116]  K. Taudorf.  Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA , 2003 .

[117]  E. Kharasch,et al.  METABOLISM OF ALFENTANIL BY CYTOCHROME P4503A (CYP3A) ENZYMES , 2005, Drug Metabolism and Disposition.

[118]  Hea‐Young Cho,et al.  Effect of cimetidine and phenobarbital on metabolite kinetics of omeprazole in rats , 2005, Archives of pharmacal research.

[119]  S. Anttila,et al.  Regulation of CYP3A5 by Glucocorticoids and Cigarette Smoke in Human Lung-Derived Cells , 2003, Journal of Pharmacology and Experimental Therapeutics.

[120]  S. Strom,et al.  In vitro and in vivo assessment of herb drug interactions. , 2006, Life sciences.

[121]  Michael D. Johnson,et al.  Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. , 2001, The Journal of pharmacology and experimental therapeutics.

[122]  L. Benet.  There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found. , 2005, Molecular interventions.

[123]  K. Thummel,et al.  In vitro and in vivo drug interactions involving human CYP3A. , 1998, Annual review of pharmacology and toxicology.

[124]  R. Riley,et al.  EVALUATION OF TIME-DEPENDENT CYTOCHROME P450 INHIBITION USING CULTURED HUMAN HEPATOCYTES , 2006, Drug Metabolism and Disposition.

[125]  W. Trager,et al.  Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. , 1994, The Journal of pharmacology and experimental therapeutics.

[126]  J. Fitzloff,et al.  Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[127]  P. Guzelian,et al.  Cyp3A regulation: from pharmacology to nuclear receptors. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[128]  Bill Gurley,et al.  Assessing the Clinical Significance of Botanical Supplementation on Human Cytochrome P450 3A Activity: Comparison of a Milk Thistle and Black Cohosh Product to Rifampin and Clarithromycin , 2006, Journal of clinical pharmacology.

[129]  Michael Zschiesche,et al.  Carbamazepine regulates intestinal P‐glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans , 2004, Clinical pharmacology and therapeutics.

[130]  R. Yumoto,et al.  Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. , 1998, European journal of pharmacology.

[131]  J. Miners,et al.  Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate , 2006, European Journal of Clinical Pharmacology.

[132]  I. Roots,et al.  Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43. , 2003, European journal of pharmacology.

[133]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[134]  Aleksandra Galetin,et al.  PREDICTION OF TIME-DEPENDENT CYP3A4 DRUG-DRUG INTERACTIONS: IMPACT OF ENZYME DEGRADATION, PARALLEL ELIMINATION PATHWAYS, AND INTESTINAL INHIBITION , 2006, Drug Metabolism and Disposition.

[135]  T. Kronbach,et al.  Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. , 1989, Molecular pharmacology.

[136]  L. Moore,et al.  Orphan Nuclear Receptors Constitutive Androstane Receptor and Pregnane X Receptor Share Xenobiotic and Steroid Ligands* , 2000, The Journal of Biological Chemistry.

[137]  Hongbing Wang,et al.  Relative Activation of Human Pregnane X Receptor versus Constitutive Androstane Receptor Defines Distinct Classes of CYP2B6 and CYP3A4 Inducers , 2007, Journal of Pharmacology and Experimental Therapeutics.

[138]  A. Ganser,et al.  Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL , 1995, Annals of Hematology.

[139]  D. Shen,et al.  Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[140]  D. Lewis,et al.  Metabolism of 2,5-bis(trifluoromethyl)-7-benzyloxy-4-trifluoromethylcoumarin by human hepatic CYP isoforms: evidence for selectivity towards CYP3A4 , 2001, Xenobiotica; the fate of foreign compounds in biological systems.

[141]  R. Tyndale,et al.  Inhibition of cytochromes P450 by antifungal imidazole derivatives. , 2002, Drug metabolism and disposition: the biological fate of chemicals.